Impact of COVID-19 on Cancer
European Cancer Organisation
177 videos
Welcome! From here you can access useful information and resources from the European Cancer Organisation, its European Cancer Summit 2022, Member Societies, Patient Advocacy Groups and Community...
Read More
Welcome! From here you can access useful information and resources from the European Cancer Organisation, its European Cancer Summit 2022, Member Societies, Patient Advocacy Groups and Community 365.
European Cancer Organisation
Speakers
Bente Mikkelsen is the Director, Non-Communicable Diseases Division of UHC/Communicable and Noncommunicable Diseases...
Bente Mikkelsen is the Director, Non-Communicable Diseases Division of UHC/Communicable and Noncommunicable Diseases World Health Organisation. She was formerly Director, Division of Noncommunicable Diseases and Promoting Health through the Life-course at the World Health Organization Regional Office for Europe (Copenhagen, Denmark), Head of Secretariat for the Global Coordination Mechanism on the prevention and control of noncommunicable diseases (WHO GCM/NCD) at the World Health Organization Headquarters (Geneva, Switzerland) from its inception in 2014 as well as a former CEO of the Southern and Eastern Norway Regional Health Authority. Dr Mikkelsen is trained as a Gynaecologist and Obstetrician and holds a Master’s degree in Health Administration and Management from the University of Oslo. Her current focus is on achieving the SDGs through the reduction of premature deaths from NCDs in the context of WHO General Programme of Work, and working across sectors with multistakeholders, within and beyond the health sector using innovation, implementation research, health literacy and new technologies.
John F. Ryan is Director, Public Health, Country Knowledge and Crisis Management, DG SANTE & Director of the...
John F. Ryan is Director, Public Health, Country Knowledge and Crisis Management, DG SANTE & Director of the Commission Public Health, country knowledge, crisis management directorate since September 2016. Previously, in the same department, he was the Head of Unit responsible for health threats, health information, the cancer programme, the pollution related disease programme, the drugs prevention programme, the health monitoring programme, the health promotion programme, the rare diseases programme and the injury prevention programme. Most recently, he led the unit responsible for health determinants and inequalities.
Kathy Oliver is Chair and founding Co-Director of theInternational Brain Tumour Alliance(IBTA), a global network...
Kathy Oliver is Chair and founding Co-Director of theInternational Brain Tumour Alliance(IBTA), a global network founded in 2005 as a dynamic worldwide community for brain tumour patient organisations and others involved in the field of neuro-oncology. Through the IBTA, Kathy is involved in advocating for equitable access to new brain tumour therapies; encouraging the establishment of brain tumour patient and carer support groups in countries where they don’t yet exist; and raising awareness of the challenges associated with this devastating disease. Kathy also participates in a range of high-level projects and committees addressing brain tumour and rare cancer issues in Europe. She is a frequent plenary and session speaker at international neuro-oncology and cancer conferences. She serves as one of two patient advocates representing Rare Diseases Europe (EURORDIS) on the recently-established European Commission Expert Group on Cancer Control. Kathy was the Patient Issues Editor on the Editorial Board for the online magazine of the European Association of Neuro-Oncology (EANO), and is on the organising committee of Rare Cancers Europe (RCE). She is Vice-Chair of the European CanCer Organisation Patient Advisory Committee (ECCO PAC) and is also a member of the European Society for Medical Oncology (ESMO) Patient Advocacy Working Group (PAWG). Kathy participated in the British Neuro Oncology Society’s National Guidelines Group for Rare Brain and CNS Tumours and on the Rare Disease UK Working Group on Patient Care and Information. She is a founder member/former board member of Cancer52, the UK umbrella group for 80 rare cancer organisations and serves on the NCRI (UK) Brain Tumour Clinical Studies Group sub group on Palliative Care and Quality of Life. Kathy is also a consumer representative for the Cochrane Neuro-Oncology Group (UK) and is a member of the Council of the British Neuro-Oncology Society (BNOS). Additionally, she is the Co-Chair of the Project Advisory Board for the European Patients’ Academy on Therapeutic Innovation (EUPATI). Kathy is an ex-freelance journalist and edits the IBTA’s annual magazine,Brain Tumour, of which approximately 14,000 copies are printed and distributed for free to recipients in 111 countries and at neuro-oncology and cancer conferences.
Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the Impact of COVID-19 on...
Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the Impact of COVID-19 on Cancer Co-Chair, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast (QUB). Mark is an internationally renowned scientist who has published over 200 papers including key publications in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut). His work has been recognised by numerous national/international awards including the Vander Molen Prize for Leukaemia Research, Ely Lilly Prize, St Lukes Medal for Cancer Research, Graves Medal for Medical Research and the prestigious 2018 European Health Award. Mark is Associate Director of Health Data Research Wales-Northern Ireland, one of 6 Health Data Research UK (HDR-UK) Substantive Sites, which is driving innovative precision medicine and population health approaches through the use of Big Data. He is Scientific Director for DATA-CAN, the UK Health Data Research Hub for Cancer. In the wake of the Cambridge Analytica/Facebook scandal, Mark led a pan European group in developing a roadmap to restore public trust in health data, published in Lancet Oncology. In the context of the recent COVID-19 pandemic, Mark is employing a data-driven approach to understand and mitigate the effects of COVID-19 on cancer patients and cancer systems Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health, an international cooperative dedicated to effective and responsible sharing of genomic/clinical data. He authored a number of key papers, including a blueprint for cancer data sharing (Nature Medicine) and a call to action for a Global Cancer Data Knowledge Network (New Engl J Med). Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer (CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal). Mark is a member of the Board of the European Alliance for Personalised Medicine (EAPM) and led the development of EAPM’s research strategy. He is also a member of the Scientific Advisory Board of the European Cancer Patient Coalition and of the Strategic Advisory Board of Genomics England. Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been translated into 17 European languages and adopted in 25 European countries. It was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. The BoR received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe which Mark received with ECCO colleagues during the 2018 European Health Forum Gastein, the premier European health policy conference. Mark’s has a particular interested in addressing cancer challenges in Central and Eastern Europe (CEE) and has highlighted the need for data-enabled research, including economic evaluation to empower cancer control strategies in the region. He is also committed to optimal pathology and laboratory medicine provision for citizens in resource-limited settings and was senior author of a paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries. He is leading the Lancet Oncology Groundshot Commission to provide the evidence base and road map for cancer research in Europe, with a particular focus on CEE countries, whose results will feed into the EU cancer mission.
Dr Mirjam Crul is Board Member, European Cancer Organisation, Special Network on the Impact of COVID-19 on Cancer...
Dr Mirjam Crul is Board Member, European Cancer Organisation, Special Network on the Impact of COVID-19 on Cancer Co-Chair and Workforce Network Co-Chair. Shereceived her master in pharmacy in 1999. Subsequently, she worked as a research fellow at the Netherlands Cancer Institute studying clinical pharmacology of novel anticancer agents. This work resulted in a PhD in 2002. She trained to become a Hospital Pharmacist from 2002-2006. Currently she is employed in the Amsterdam University Medical Center, where she is the Head of the Aseptic Compounding Unit and has pharmaceutical responsibility for the Oncology Department. She served as a Board Member for the Dutch Hospital Pharmacists Association (NVZA) from 2016 to 2019. At present, she holds a chair in the European Cancer Organisation Board and is Vice-President of the European Society of Oncology Pharmacy (ESOP).
Rapporteur, Special Committee on Beating Cancer, Shadow Rapporteur, EU4Health; Member, EU Special Committee on...
Rapporteur, Special Committee on Beating Cancer, Shadow Rapporteur, EU4Health; Member, EU Special Committee on Beating Cancer; Member, ENVI Committee and Co-Chair of MEPs Against Cancer, Oncologist